Silexion Therapeutics completes initial study of SIL-204 in pancreatic cancer models, assessing tumor growth and metastasis. Results expected in March 2025. Silexion Therapeutics Corp. announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results